Donanemab in Canada: approval, access and what comes next
October 10, 2026
What Canadians should know
This spring, Canada reached an important milestone in Alzheimer’s disease treatment when Health Canada approved donanemab for eligible people with mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Donanemab is a disease-modifying therapy designed to act on the underlying biology of Alzheimer’s by targeting and removing amyloid plaques in the brain. It is not a cure and cannot reverse existing damage, but it may slow disease progression for some eligible people.
Since the approval, the conversation has shifted from whether donanemab can be used in Canada to the more complicated questions of who may benefit, how people will access it, and whether health plans will cover its cost.
On April 30, 2026, Health Canada issued a Notice of Compliance for donanemab, with the approval publicly announced in early May. It became the second disease-modifying Alzheimer’s treatment approved in Canada, following lecanemab.
Why early diagnosis matters
Disease-modifying therapies such as donanemab are intended for use during the earlier stages of Alzheimer’s disease. This makes recognizing symptoms and receiving a timely, accurate diagnosis especially important.
Treatment cannot restore abilities already lost or reverse damage caused by Alzheimer’s disease. People who may be eligible need to be identified while they are experiencing mild cognitive impairment or mild dementia, before their condition progresses beyond the stage for which treatment is authorized.
An earlier diagnosis can also give people and their families more time to explore treatment and support options, make informed decisions and plan for the future.
Who may be eligible for donanemab?
Health Canada’s authorization is specific. Donanemab is approved for adults who:
- Have a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease.
- Have confirmed amyloid pathology in the brain.
- Are ApoE ε4 non-carriers or heterozygotes, meaning they carry no more than one copy of the ApoE ε4 gene variant.
This means donanemab is not suitable for everyone living with dementia, or even everyone with Alzheimer’s disease. Determining eligibility requires an early and accurate diagnosis, confirmation of amyloid pathology and genetic testing.
Donanemab is also delivered by intravenous infusion. Patients require ongoing medical monitoring, including MRI scans, because therapies in this class can cause amyloid-related imaging abnormalities, known as ARIA. These abnormalities can include swelling or bleeding in the brain.
Anyone with questions about eligibility, benefits or risks should speak with a qualified health-care provider.
Approval does not mean insurance coverage
Health Canada’s approval allows donanemab to be marketed and prescribed in Canada. It does not mean the medication is automatically paid for by provincial or territorial health plans.
At present, donanemab is not routinely covered through Canada’s public drug plans. Private insurance access may also vary by provider, policy and province or territory. Without reimbursement, the cost may remain a significant barrier for families.
In September, Canada’s Drug Agency issued a positive draft recommendation supporting public reimbursement for eligible people with mild cognitive impairment or early-stage Alzheimer’s disease. This was an important step, but a draft recommendation does not itself provide coverage. Provincial and territorial governments must still make their own funding and implementation decisions.
What happens next for donanemab in Canada?
The next chapter for donanemab in Canada centres on access and health-system readiness.
Access will depend not only on reimbursement decisions, but also on health-system readiness. Eligible patients will need amyloid and genetic testing, infusion services, MRI monitoring and health-care professionals equipped to assess and manage treatment.
Donanemab is not a cure. But for people living with Alzheimer’s disease and their families, its approval represents an important shift: the availability of therapies designed to act on the underlying biology of the disease and potentially slow its progression.
At CLEAR, developments like these reinforce why sustained investment in dementia research matters. Every new treatment builds on years of scientific discovery. Continued support is essential to advancing earlier diagnosis, developing more effective therapies and, ultimately, creating a future where Alzheimer’s disease and related dementias are preventable, treatable and curable.